NORD gratefully acknowledges Morie A. Gertz, MD, Hematology and Internal Medicine, Mayo Clinic, for assistance in the preparation of this report.
The specific symptoms, age of onset, and rate of progression of multiple myeloma varies from case to case. Some affected individuals will not exhibit any symptoms (asymptomatic). Multiple myeloma may progress to cause life-threatening complications. It is important to note that affected individuals will not have all the symptoms listed below.
The most common symptom associated with multiple myeloma is bone pain, usually of the lower back or ribs. In most cases, movement worsens the pain, which may be mild, moderate or severe. Affected individuals are usually more susceptible to fractures than the general population and may experience repeated fractures of affected bones. The bones of the spine may become involved, potentially collapsing and resulting in spinal cord compression. Compression of the spinal cord results in pain, weakness and numbness in the arms and legs.
Another possible sign of multiple myeloma is an elevated level of calcium in the blood, a condition called hypercalcemia. This occurs because damage to bones often results in the release of calcium into the bloodstream. Abnormally high levels of calcium may result in nausea, lack of appetite, fatigue, abdominal pain, muscle pain and weakness, excessive thirst, and/or confusion.
Overproduction of plasma cells may also hinder the production and decrease the effectiveness of other cells of the body resulting in a variety of symptoms. Affected individuals may experience low levels of circulating red blood cells (anemia) resulting in weakness, fatigue, dizziness, shortness of breath, and lack of color (pallor). Affected individuals may also experience low levels of cells that assist in clotting (platelets), a condition known as thrombocytopenia. Symptoms associated with thrombocytopenia include abnormal bleeding episodes that often result in purplish discoloration of the skin resulting from bleeding (hemorrhaging) of small blood vessels near the surface of the skin (purpura). Affected individuals may rarely experience repeated nosebleeds (epistaxis).
Affected individuals may also experience low levels or reduced effectiveness of white blood cells, which weakens the immune system and results in affected individuals becoming more susceptible than the general population to developing recurrent bacterial infections. The most common infection is pneumonia. In some cases, recurrent infections may be the first apparent symptom of multiple myeloma.
Individuals with multiple myeloma may also develop kidney abnormalities. In some cases, hypercalcemia may cause kidney damage. In some cases, abnormal proteins found in the blood or urine (M-proteins), which are produced by myeloma cells, may cause kidney damage (myeloma kidney). Kidney abnormalities may develop slowly or rapidly, and may eventually progress to cause kidney (renal) failure.
In rare cases, individuals with multiple myeloma may have an abnormally large liver (hepatomegaly) or spleen (splenomegaly). In rare cases, multiple myeloma may occur in association with other disorders. The three most common disorders that may occur in association with multiple myeloma include hyperviscosity syndrome, cryoglobulinemia, or amyloidosis.
Hyperviscosity syndrome is characterized by the blood becoming abnormally thick and sticky due to the abnormal accumulation of M-proteins in the blood. As a result blood flow is slowed. Hyperviscosity syndrome may cause headaches, fatigue, frequent bruising, gastrointestinal bleeding, and vision abnormalities such as disease of the retina (retinopathy).
Cryoglobulinemia is a rare disorder that occurs due to the accumulation of abnormal proteins (cryoglobulins) in the bloodstream. These proteins thicken or gel on exposure to cold. In some cases there are no symptoms. In others a variety of symptoms may develop. The most common symptoms are joint pain (arthralgia), pain and numbness in the fingers and toes in response to cold (Raynaud’s phenomenon), weakness, and purpura.
Amyloidosis is a rare disorder characterized by the abnormal accumulation of a fibrous protein (amyloidosis) in tissues of the body. The excessive accumulation of amyloid causes an affected organ to malfunction. (For more information on this disorder, see the Related Disorders section below.)
The exact cause of multiple myeloma is not known. Symptoms occur as a result of a process that is initiated by the abnormal multiplication of plasma cells in bone marrow. Scientists suspect there may be a variety of causes that may include environmental factors (e.g., the effects of exposure to radiation), genetic abnormalities, and/or additional factors that may play varying contributing roles.
One factor of interest to researchers is that many myeloma cells have been found to be missing all or part of chromosome 13. Also, the development of multiple myeloma is related in virtually all cases to a condition called monoclonal gammopathy of undetermined significance or MGUS (see Related Disorders section). The cause of MGUS is not known.
The specific symptoms of multiple myeloma result from excessive and unnecessary growth (neoplastic proliferation) of plasma cells.
Multiple myeloma is a rare cancer that is slightly more common in males than females. In 2012, more than 21,700 individuals in the United States were diagnosed with this disease. It is believed that approximately 100,000 Americans currently have the disease.
According to reports in the medical literature, multiple myeloma accounts for approximately one percent of all malignancies in Caucasians and about two percent of all malignancies in individuals of African descent. It accounts for 10 percent of all hematological malignancies in the United States. The yearly incidence rate is estimated to be approximately four persons out of 100,000.
Multiple myeloma usually becomes apparent between the fourth and seventh decades of life, with a median age of 68 years at diagnosis. The occurrence of the disease before the age of 40 is rare.
A diagnosis of multiple myeloma is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Such tests may include removal and microscopic examination of small samples of bone marrow (biopsy or aspiration), blood tests to detect low levels of red and white blood cells, and various x-ray techniques including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scanning that may reveal characteristic changes to bones. A test that uses electric currents to sort proteins in the blood or urine (electrophoresis) may be used to detect elevated levels of M-proteins.
The diagnosis and therapeutic management of multiple myeloma may require the coordinated efforts of a team of medical professionals, such as physicians who specialize in the diagnosis and treatment of cancer (medical oncologists), disorders of the blood and blood-forming tissues (hematologists), or the use of radiation to treat cancers (radiation oncologists); oncology nurses; surgeons; dietitians; and/or other professionals.
Specific therapeutic procedures and interventions may vary, depending upon numerous factors, such as disease stage; tumor size; the presence or absence of certain symptoms; individual’s age and general health; and/or other elements. Decisions concerning the use of particular drug regimens and/or other treatments should be made by physicians and other members of the health care team in careful consultation with the patient based upon the specifics of his or her case; a thorough discussion of the potential benefits and risks, including possible side effects and long-term effects; patient preference; and other appropriate factors.
In some cases, affected individuals may have a slow developing form of multiple myeloma that progresses over many years, often without symptoms (asymptomatic). Such individuals, and individuals with similar conditions like smoldering multiple myeloma and MGUS, may not require treatment. However, these individuals should be routinely monitored so that treatment can begin if symptoms appear.
The treatment of multiple myeloma usually involves chemotherapy to reduce the numbers of abnormal plasma cells, drugs to help fight infection (e.g., antibiotics), and medications to reduce pain (analgesic drugs). Additional treatment may include the use of high energy x-rays (radiation therapy) to destroy cancer cells and reduce bone masses that may develop. The use of new biologic drugs may also be recommended. If affected individuals experience involvement of the kidneys, fluids may need to be administered to avoid dehydration.
The following link provides information from the National Cancer Institute about medications that have been approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma:
Stem-cell transplantation along with high-dose chemotherapy is regularly used for the treatment of multiple myeloma. Stem cells, which reside in the bone marrow, function as “parent” cells, undergoing a series of divisions that result in the formation of all the different types of blood cells (e.g., red blood cell, platelets, etc.).
Other treatment is symptomatic and supportive.
Information on current clinical trials for multiple myeloma is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (800) 411-1010
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Recombinant erythropoietin may be used as a treatment for anemia in some individuals with multiple myeloma. Recombinant erythropoietin is an artificial (synthetic) version of a natural hormone that stimulates the growth of red blood cells.
Researchers are studying the drug, denosumab (AMG 162) for the treatment of individuals with multiple myeloma. Denosumab suppresses bone turnover, a normal process in which bone gradually breaks down (bone resorption) and then reforms. A phase I clinical trial of individuals with multiple myeloma demonstrated rapid suppression of bone turnover. Further clinical trials are ongoing. More research is necessary to determine the long-term safety and effectiveness of this potential treatment for multiple myeloma.
Results from a multicenter phase III clinical study suggest that bortezomib plus melphalan and prednisone is effective for untreated elderly individuals with multiple myeloma. Bortezomib plus melphalan and prednisone was significantly superior to melphalan and prednisone. More research is necessary to determine the long-term safety and effectiveness of this treatment for elderly untreated individuals with multiple myeloma.
Contact for additional information about Multiple Myeloma:
Morie A. Gertz, MD
Hematology and Internal Medicine
200 First Street S.W.
Rochester, MN 55905
RareConnect offers a safe patient-hosted online community for patients and caregivers affected by this rare disease. For more information, visit www.rareconnect.org.
Beers MH, Berkow R, eds. The Merck Manual. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:965-68.
Kyle RA. Plasma cell disorders. In: Fauci, AS, et al., eds. Harrison’s Principles of Internal Medicine. 14th Ed.; McGraw-Hill, Inc., 1998:962-65.
Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia, PA: W.B. Saunders Co; 1996:713-17.
Hoffman R, et al, eds. Hematology Basic Principles and Practice, 2nd ed. New York, NY: Churchill-Livingstone, Inc; 1995:1360-67.
Kumar SK, Mikhael JR, Buadi FK, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma:Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc. 2009;84(12):1095-1110.
Mateos MV, et al., Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood. 2006; 108(7):2165-72.
Dougall, Chaisson M. A monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases. Clin Calcium. 2006;16:95-103.
Body JJ, et al., A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosuma, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12:1221-8.
Berenson JR. Zoledronic acid in cancer patients with bone metastases: Results of Phase I and II trials. Semin Oncol. 2001;28:25-34.
Kyle RA. Diagnostic challenges and standard therapy. Semin Hematol. 2000;38:11-14.
Kneller A, et al. Therapy with thalidomide in refractory multiple myeloma patients – the revival of an old drug. Br J Haematol. 2000;108:391-93.
Kyle RA, et al. Monoclonal gammopathy of undetermined significance. Hematol Oncol Clin North Am. 1999;13:1181-202.
Brigden ML. The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance? Postgrad Med. 1999;106:135-42.
Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.
Attal M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med. 1996;335:91-97.
Berenson JR, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med. 1996;334:488-93.
Wahlin A, et al. Effects of plasmapheresis on the plasma concentration of proteins used to monitor the disease process in multiple myeloma. Acta Med Scand. 1988;223:263-67.
Cooper MR, et al. Interferons in the treatment of multiple myeloma. Cancer. 1987;59:594-600.
Costanzi JJ, et al. The use of interferon in the treatment of multiple myeloma. Semin Oncol. 1987; 4:24-28.
Mayo Foundation for Medical Education and Research. Multiple Myeloma. Last Updated: August 16, 2011. Available at: http://www.mayoclinic.com/invoke/cfm?id=DS00415 Accessed:March 7, 2013.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100